Fact Sheet: President Donald J. Trump Announces First Deal To Bring Most-Favored-Nation Pricing To American Patients

The document was released on September 30, 2025, by the White House. It presents the terms of an arrangement between the Trump Administration and Pfizer that is intended to ensure lower prices for some of Pfizer's prescription medicines for U.S. consumers. The stated purpose of the agreement is to bring American drug prices in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: